Clinical trials
Essential Thrombocythemia clinical trials
Below are recruiting essential thrombocythemia clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05835466RecruitingPhase 2
Reparixin for myelofibrosis patients who can’t use JAK inhibitors
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Tampa, FloridaAges 18 years+ - NCT05440838Recruiting
Study factors that predict response to first-line blood cancer therapy
This study looks for factors that may predict how well people with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis respond to first treatments such as hydroxyurea or pegylated interferon. It may help doctors choose better treatments by learning what differences affect outcomes.
AngersAges 18 years+ - NCT05320198RecruitingPhase 1/Phase 2
Testing DISC-0974 for anemia in myelofibrosis or MDS
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Gilbert, ArizonaAges 18 years+ - NCT05198960RecruitingPhase 3
Blood thinner drugs vs aspirin to prevent clot problems
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
AngersAges 18 years+ - NCT05123365RecruitingPhase 1/Phase 2
Testing a dose of N-acetylcysteine for certain blood cancers
This Phase 1/2 study tests what dose of N-acetylcysteine (NAC) is safe and potentially helpful for people with essential thrombocythemia, polycythemia vera, or myelofibrosis. It focuses on people who still have symptoms and meet blood and health requirements so researchers can monitor side effects and symptom changes.
Irvine, CaliforniaAges 18 years+ - NCT04942080Recruiting
Using CALR test results to track certain blood cancers
This study looks at how much of a specific gene change (CALR) you have, and whether it helps doctors diagnose and follow people with certain blood cancers over time. It mainly involves using samples and medical data rather than testing a new drug.
AngersAges 18 years+ - NCT04645199Recruiting
Long-term follow-up study for blood and bone marrow diseases
This study is collecting long-term follow-up information from people diagnosed with certain blood and bone marrow conditions. It may help doctors understand what happens over time and improve future care, but you’re mainly contributing data rather than receiving a new treatment.
Tianjin, Tianjin MunicipalityAges Any age - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+
Hear when a new Essential Thrombocythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for essential thrombocythemia?
- Yes. Clin2 currently lists 32 recruiting essential thrombocythemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a essential thrombocythemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a essential thrombocythemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.